Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCB | P05771 | 18/20 | 0.63 |
| ▸ | PRKCA | P17252 | 18/20 | 0.63 |
| ▸ | PRKCD | Q05655 | 14/20 | 0.63 |
| ▸ | PRKCH | P24723 | 12/20 | 0.63 |
| ▸ | PRKCE | Q02156 | 12/20 | 0.63 |
| ▸ | PRKCQ | Q04759 | 12/20 | 0.63 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR1E | P28566 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR5A | P47898 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | PRKACG | P22612 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3546567 | 0.84 | PRKCB (0.75) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL15758294 | 0.84 | PRKCH (0.55) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL14555041 | 0.81 | PRKCB (0.67) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3579506 | 0.79 | PRKCB (0.75) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3541633 | 0.78 | PRKCB (1.00) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL15758297 | 0.76 | PRKCH (0.46) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3543653 | 0.74 | PRKCB (0.59) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3543163 | 0.73 | PRKCB (0.79) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3536117 | 0.73 | PRKCB (0.79) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3545652 | 0.73 | PRKCB (0.62) | PRKCBPRKCAPRKCDPRKCHPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446043-B2 | Pharmaceutical combinations | NOVARTIS AG (CH) | 2016-09-20 | — | — | US | claimed |
| US-20150306101-A1 | Pharmaceutical Combinations | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2015-10-29 | — | — | US | claimed |
| US-8748428-B2 | Use of a PKC inhibitor | NOVARTIS AG (CH) | 2014-06-10 | — | — | US | claimed |
| EP-2552428-A1 | PKC INHIBITORS FOR THE TREATMENT OF B-CELL LYMPHOMA HAVING CHRONIC ACTIVE B-CELL-RECEPTOR SIGNALLING | Novartis AG (CH) | 2013-02-06 | — | — | EP | claimed |
| WO-2011120911-A1 | PKC INHIBITORS FOR THE TREATMENT OF B-CELL LYMPHOMA HAVING CHRONIC ACTIVE B-CELL-RECEPTOR SIGNALLING | NOVARTIS AG (CH) | 2011-10-06 | — | — | WO | claimed |
| US-20110245256-A1 | USE OF A PKC INHIBITOR | NOVARTIS AG (CH) | 2011-10-06 | — | — | US | claimed |
| EP-3600440-A1 | REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS | Sienna Biopharmaceuticals, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2020023389-A1 | REDUCED EXPOSURE COMPOSITIONS MODULATING THERAPEUTIC TARGETS | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2018175302-A1 | POLYMER CONJUGATES TARGETING C-SRC WITH REDUCED EXPOSURE | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018175340-A1 | REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| EP-2925366-B1 | PHARMACEUTICAL COMBINATIONS | NOVARTIS AG (CH) | 2018-02-21 | — | — | EP | disclosed |
| US-9446043-B2 | Pharmaceutical combinations | NOVARTIS AG (CH) | 2016-09-20 | — | — | US | disclosed |
| US-20150306101-A1 | Pharmaceutical Combinations | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2015-10-29 | — | — | US | disclosed |
| US-8748428-B2 | Use of a PKC inhibitor | NOVARTIS AG (CH) | 2014-06-10 | — | — | US | disclosed |
| WO-2014085381-A1 | PHARMACEUTICAL COMBINATIONS | NOVARTIS AG (CH) | 2014-06-05 | — | — | WO | disclosed |
| EP-2552428-A1 | PKC INHIBITORS FOR THE TREATMENT OF B-CELL LYMPHOMA HAVING CHRONIC ACTIVE B-CELL-RECEPTOR SIGNALLING | Novartis AG (CH) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011120911-A1 | PKC INHIBITORS FOR THE TREATMENT OF B-CELL LYMPHOMA HAVING CHRONIC ACTIVE B-CELL-RECEPTOR SIGNALLING | NOVARTIS AG (CH) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011120911-A1 | PKC INHIBITORS FOR THE TREATMENT OF B-CELL LYMPHOMA HAVING CHRONIC ACTIVE B-CELL-RECEPTOR SIGNALLING | NOVARTIS AG (CH) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245256-A1 | USE OF A PKC INHIBITOR | NOVARTIS AG (CH) | 2011-10-06 | — | — | US | disclosed |
| US-20110245256-A1 | USE OF A PKC INHIBITOR | NOVARTIS AG (CH) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245256-A1 | USE OF A PKC INHIBITOR | CD79B, PRKCB, BCL9 | PRKCB 2/4885PRKCA 4/4885PRKCD 15/4885 |
| US-20150306101-A1 | Pharmaceutical Combinations | MAP2K1, PRKACA, MAP2K2 | PRKCB 4/4885PRKCA 6/4885PRKCD 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.